[{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz to initiate phase III clinical trial of centhaquine","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Highlights Positive Impacts of Centhaquine on COVID-19 Patients.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sovateltide Significantly Improved Clinical Outcome in Patients with Acute Cerebral Ischemic Stroke When Compared to Standard of Care","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Receives Marketing Authorization for Lyfaquin\u2122 (centhaquine) from Indian Regulatory Agency","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyfaquin\u00ae, a First-in-class Resuscitative Agent for Patients with Excessive Blood Loss, to be Launched in India","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resuscitative Effect of Centhaquine (Lyfaquin\u00ae) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sovateltide (PMZ-1620), a First-in-Class Investigational Product, Shows Promise to Slow Down the Progression of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approved IND Submitted by Pharmazz, Inc. to Initiate a Phase III Clinical Trial of Centhaquine in Patients with Hypovolemic Shock","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Inc. Submits Investigational New Drug Application to India Central Drugs Standard Control Organization for a Phase II clinical trial of Sovateltide (PMZ-1620) in Hypoxic-ischemic Encephalopathy in Neonates","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Inc. Announces Indian Central Drugs Standard Control Organization (CDSCO) Clearance of IND to Conduct a Phase II Clinical Trial of Sovateltide (PMZ-1620) in Hypoxic-Ischemic Encephalopathy in Neonates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Inc. Presents Data From its Positive Phase III Study of Centhaquine (PMZ-2010) as a Resuscitative Agent in Hypovolemic Shock Patients at Upcoming Military Health System Research Symposium","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Inc. Announces Two Presentations on Sovateltide as a Treatment for Acute Ischemic Stroke at the 14th World Stroke Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sovateltide","moa":"ETB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Inc. Presents Positive Results of Phase III Clinical Trial Demonstrating Sovateltide\u2019s Efficacy as a Treatment for Acute Cerebral Ischemic Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sovateltide","moa":"ETB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Phase III Trial Results Demonstrating Sovateltide's Efficacy to Treat Acute Cerebral Ischemic Stroke Presented at The International Stroke Conference 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz, Inc. Announces US FDA Clearance for a Phase III Clinical Trial of Sovateltide (PMZ-1620) in Acute Cerebral Ischemic Stroke Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz, Inc. Announces Marketing Approval of Sovateltide in India for Acute Cerebral Ischemic Stroke Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmazz Inc. and Sun Pharma Enter into Licensing Agreement for Introducing Tyvalzi\u2122 (sovateltide) in India","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Special Protocol Assessment Agreement Reached with the U.S. Food and Drug Administration for Phase 3 Clinical Trial of Sovateltide for The Treatment of Acute Cerebral Ischemic Stroke Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Dr. Reddy\\'s Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmazz Inc. and Dr. Reddy's Laboratories have Entered into a Licensing Agreement to Market Centhaquine (Lyfaquin) as a Resuscitative Agent for Hypovolemic Shock in India","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Centhaquine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Dr. Reddy's Laboratories"}]
Find Clinical Drug Pipeline Developments & Deals by Pharmazz
Details :
Under the agreement, Dr. Reddy's has received exclusive rights to market and distribute a first-in-class innovative drug Lyfaquin in India. Developed by Pharmazz, Centhaquine is a resuscitative agent presently indicated for treating hypovolemic shock.
Details :
Tycamzzi (Sovateltide), is a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, which is investigated for the treatment of acute cerebral ischemic stroke patients.
Details :
Underf the agreement, Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi, a selective endothelin B receptor agonist and a new first-in-class drug recently approved for treating cerebral ischemic stroke.
Details :
Tycamzzi, a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, receives marketing approval in India for the treatment of acute cerebral ischemic stroke. Sovateltide is in Phase 3 trial in US for the sa...
Details :
Tycamzzi (sovateltide) is a highly selective endothelin-B receptor agonist, having the potential to be a neuronal progenitor cell therapeutics with anti-apoptotic activity that improves cerebral blood flow and neurological outcome in acute cerebral ische...
Details :
Results of this trial shows highly encouraged regarding the potential of Tycamzzi (sovateltide) to be the first therapeutic since tPA to demonstrate a positive impact on patients suffering from acute ischemic stroke.
Details :
PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke pa...
Details :
Tycamzzi (sovateltide), an endothelin-B receptor agonist, has been previously shown to increase cerebral blood flow, have anti-apoptotic activity and produce neurovascular remodeling when administered IV following acute cerebral ischemic stroke in rats.
Details :
The positive results seen in the Phase III study indicate that Lyfaquin (centhaquine) is a highly safe and efficacious resuscitative agent as an adjuvant to the standard of care and would be a addition to the U.S. Military’s medical resources that can ...
Details :
PMZ-1620 (sovateltide) is endothelin-B receptor agonist that increases blood flow, shows anti-apoptotic activity, protects neural mitochondria, and produces neurovascular remodeling. Sovateltide is undergoing MA review by CDSCO for acute cerebral ischemi...